33
views
0
recommends
+1 Recommend
0 collections
    4
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Voluminous Pancreatic Mucinous Cystadenoma in a Non-Pregnant Woman with Rheumatoid Arthritis

      letter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, Indeed, cystic tumors of the pancreas are rare and account for 10–15% of pancreatic neoplasms.[1] There are four main categories of pancreatic cystic tumors including i) Mucinous cystic tumors (MCTs); ii) Serous cystic tumors (SCTs); iii) Intraductal papillary cystic tumors (IPCTs); and iv) Papillary cystic tumors. [2][3]Mucinous cystic neoplasm of the pancreas is an uncommon tumor characterized by an inner mucin-producing columnar epithelium layer and an outer dense cellular ovarian-like stromal layer. These tumors are typically localized in the body and tail of the pancreas and do not communicate with the pancreatic ductal system. [1][4] According to the studied reported so far, MCTs are found more commonly in females, especially in middle-aged more often than the elderly, and therefore are sex hormone- sensitive. [3][4] Most of the large MCTs reported to date were in pregnant women and supposed to be due to over expression of sex hormones during this period. [5][6][7][8][9]This is the first report of a huge MCT in a non-pregnant woman with rheumatoid arthritis having been under corticosteroids treatment. A 50-year-old woman was referred to Shahid Beheshti Hospital, Babol, Iran because of abdominal pain, distention and left abdominal mass. The patient was non-alcoholic with no history of gallbladder or pancreatitis. She had only a history of rheumatoid arthritis diagnosed at 42 years of age and had been under prednisolone (a corticosteroid) treatment. Physical examination suggested the presence of a mass in the left hypocondrium. Abdominal CT scan proved this finding. The patient underwent tumor resection with distal pancreatectomy due to the size and difficult handling of the tumor. A voluminous mass was found originating from the pancreatic body-tail (Figure 1). No evidence of invasive or metastatic tumor spread was observed within the abdomen. Pathological examination showed a 23×11×14 cm multilocular tumor, weighted 3065 g and pinkish gray. The cyst had a smooth internal surface filled with dark brown fluid. Microscopically, the cyst wall lined by mucin-producing columnar epithelium associated with an outer dense cellular ovarian- like stroma. The histological diagnosis was a mucinuos cystic neoplasm (musinous cystadenoma). The postoperative course was uneventful and the patient discharged 6 days after surgery in good general condition. After 6 months follow up, the patient was in good health and presented no signs of recurrence. However, the unusual size of the tumor was in contrast to the findings from other reports, since the patient was not pregnant with the cyst showing no sign of malignancy. Up to now, most of the large reported MCTs were in pregnant women and supposed to be due to over expression of sex hormones during this period. [5][6][7][8][9]This is the first case of a huge MCT in a nonpregnant woman with rheumatoid arthritis having been under corticosteroids treatment. There is also another case reporting a large MCT in the appendix of a rheumatoid arthritis patient treated with steroids.[10] To date, there is less done to identify the presence of various steroid receptors in MTNs. These studies indicate estrogen and progesterone receptors in the mass.[11][12][13] Since the presence of other steroid receptors, especially glucocorticoid receptors has not been proven in MCTs, it is likely that prednisolone cause irregular mass overgrowth by interacting with its possible glucocorticoid receptors. In this regard, over expression of glucocorticoid receptors in human pancreatic cancer has been shown in one study.[14] Therefore we suggest that steroids side effects, especially in patients with potentially malignant tumors, be investigated further. Fig. 1 A huge cystic mass was found originating from body to tail of the pancreas.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors.

          The clinicopathological features of 56 patients with mucinous cystic tumors (MCTs) of the pancreas were studied. Particular attention was paid to the prognosis of MCTs and the relationship to their ovarian, hepatic, and retroperitoneal counterparts. To distinguish MCTs from pancreatic intraductal papillary-mucinous tumors, MCTs were defined as tumors lacking communication with the duct system and containing mucin-producing epithelium, usually supported by ovarian-like stroma. All 56 tumors occurred in women (mean age 48.2 years) and were preferentially (93%) located in the body and tail of the pancreas. In accordance with the WHO classification, MCTs were divided into adenomas (n = 22), borderline tumors (n= 12), and noninvasive and invasive carcinomas (n = 22). Survival analysis revealed the extent of invasion to be the most significant prognostic factor (p<0.0001). Malignancy correlated with multilocularity and presence of papillary projections or mural nodules, loss of ovarian-like stroma, and p53 immunoreactivity. Stromal luteinization with expression of tyrosine hydroxylase, calretinin, or alpha inhibin was found in 66% of the cases. We conclude that the biologic behavior of MCTs is predictable on the basis of the extent of invasion. The similarities (i.e. gender, morphology, stromal luteinization) between pancreatic MCT and its ovarian, hepatobiliary, and retroperitoneal counterparts suggest a common pathway for their development.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases.

            Mucinous cystic neoplasms (MCNs) of the pancreas are uncommon tumors. The classification and biologic potential of these neoplasms remain the subject of controversy. Attempts to classify these tumors in a similar manner to ovarian MCNs remains controversial, as even histologically benign-appearing pancreatic MCNs metastasize and are lethal. One hundred thirty cases of MCNs were identified in the files of the Endocrine Pathology Tumor Registry of the Armed Forces Institute of Pathology from the years 1979 to 1993. The pathologic features, including hematoxylin and eosin staining, histochemistry, immunohistochemistry (IHC), cell cycle analysis, and K-ras oncogene determination were reviewed. These findings were correlated with the clinical follow-up obtained in all cases. There were 130 women, aged 20-95 years (mean age at the outset, 44.6 years). The patients had vague abdominal pain, fullness, or abdominal masses. More than 95% of the tumors were in the pancreatic tail or body and were predominantly multilocular. The tumors ranged in size from 1.5 to 36 cm in greatest dimension, with the average tumor measuring >10 cm. A spectrum of histomorphologic changes were present within the same case and from case to case. A single layer of bland-appearing, sialomucin-producing columnar epithelium lining the cyst wall would abruptly change to a complex papillary architecture, with and without cytologic atypia, and with and without stromal invasion. Ovarian-type stroma was a characteristic and requisite feature. Focal sclerotic hyalinization of the stroma was noted. This ovarian-type stroma reacted with vimentin, smooth muscle actin, progesterone, or estrogen receptors by IHC analysis. There was no specific or unique epithelial IHC. K-ras mutations by sequence analysis were wild type in all 52 cases tested. Ninety percent of patients were alive or had died without evidence of disease (average follow-up 9.5 years), irrespective of histologic appearance; 3.8% were alive with recurrent disease (average 10 years after diagnosis); and 6.2% died of disseminated disease (average 2.5 years from diagnosis). Irrespective of the histologic appearance of the epithelial component, with or without stromal invasion, pancreatic MCNs should all be considered as mucinous cystadenocarcinomas of low-grade malignant potential. Pancreatic MCNs cannot be reliably or reproducibly separated into benign, borderline, or malignant categories.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pancreatic cystic tumors.

              Cystic tumors of the pancreas are less frequent than other tumors in neoplastic pancreatic pathology, but in recent years the literature has reported an increasing number. After the first report by Becourt in 1830, cystic tumors were classified into 2 different types by Compagno and Oertel in 1978: benign tumors with glycogen-rich cells and mucinous cystic neoplasms with overt and latent malignancy. The WHO classification of exocrine tumors of the pancreas, published in 1996, is based on the histopathological features of the epithelial wall, which are the main factor in differential diagnosis with cystic lesions of the pancreas. Thanks to the knowledge acquired up to now, a surgical procedure is not always required because the therapeutic choice is conditioned by the correct classification of this heterogeneous group of tumors. Clinical signs are not really useful in the clinical work up, most patients have no symptoms and when clinical signs are present, they may help us to pinpoint the organ of origin but never to identify the type of pathology. In the last few years, the great improvement in imaging has enabled us not only to discriminate cystic from solid lesions, but also to identify the features of the lesions and label them preoperatively. More invasive diagnostic procedures such as fine needle aspiration and intracystic fluid tumor marker level are not really useful because they are not sensitive and the cystic wall can show different degrees of dysplasia and de-epithelialization. These are the reasons for sending the entire specimen to pathology. Good cooperation between surgeons, pathologists, radiologists and gastroenterologists is mandatory to increase the chances of making a proper diagnosis. Therefore, we must analyze all the information we have, such as age, sex, clinical history, location of the tumor and radiological features, in order to avoid the mistake of treating a cystic neoplasm as a benign lesion or as a pseudocyst, as described in the literature. Except for inoperable cases due to the critical condition of the patient or non-resectable lesions, surgical treatment differs with the diagnosis. Cystic tumors of the pancreas, therefore, are a heterogeneous group of tumors, with a real problem regarding differential diagnosis between neoplastic and inflammatory lesions. Even with a proper work up, some perplexity may remain about the nature of the lesion and in these cases the surgical procedure has a therapeutic value as well as playing a diagnostic role. The role of surgery is central in the treatment of these tumors because it could be curative when complete resection is possible. In this way, the lack of good therapeutic results with chemotherapy and radiotherapy force the surgeon to go ahead with the procedure. Intraductal papillary mucinous neoplasms represent a new and, from the epidemiological point of view, important chapter in the world of cystic tumors. The margin of resection is important and the surgeon has to be aware that in order to have a curative resection, total pancreatectomy is sometimes required. In the last few years the therapeutic approach has changed thanks to new knowledge of the biological behavior of these tumors. In fact, from a surgical approach in all cases, we are now discussing the possibility of a follow-up not only for asymptomatic serous cystadenomas but also for the little branch side intraductal papillary mucinous neoplasms (IPMNs) in critical patients. A follow-up could be planned even for solid pseudopapillary tumors but it seems risky to leave untreated big tumors in young patients without a certain diagnosis and with so few studies reported in the literature.
                Bookmark

                Author and article information

                Journal
                Iran Red Crescent Med J
                Iran Red Crescent Med J
                Kowsar
                Iranian Red Crescent Medical Journal
                Kowsar
                2074-1804
                2074-1812
                August 2011
                01 August 2011
                : 13
                : 8
                : 595-596
                Affiliations
                [1 ]Department of Surgery, Babol University of Medical Sciences, Babol, Iran
                [2 ]Department of Pathology, Babol University of Medical Sciences, Babol, Iran
                [3 ]Clinical Research Development Center, Shahid Beheshti Hospital, Babol, Iran
                Author notes
                [* ]Correspondence: Sepideh Siadati, MD, Department of Pathology, Bobol University of Medical Sciences, Babol, Iran. Tel.: +98-9113232911, Fax: +98-1112266192, E-mail: siadati_sepideh@ 123456yahoo.com
                Article
                3371992
                22737534
                ec018d45-9eb8-4bc3-b5a0-c59d17061c6a
                Copyright © 2011, Kowsar M.P. Co.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 12 November 2010
                : 26 February 2011
                Categories
                Letter to Editor

                Medicine
                pancreas,rheumatoid arthritis,mucinous cystadenoma
                Medicine
                pancreas, rheumatoid arthritis, mucinous cystadenoma

                Comments

                Comment on this article